Navigation Links
Hovione Buys Drug Manufacturing Facility in China
Date:3/6/2008

LOURES, Portugal, March 6 /PRNewswire/ -- Hovione announces that it has purchased 75% of Hisyn Pharmaceutical Co. Limited. The Zhejiang provincial authorities have already issued the necessary business license and the joint venture (JV) is now operational.

The acquisition provides Hovione with significant additional drug substance manufacturing production capacity and strengthens its 20 year presence in China. The acquisition includes both development labs in Shanghai and an active pharmaceutical ingredient (API) plant occupying 22,000 square meters. on a 22 acre plot employing 181 staff. Hovione's relationship with Hisyn started with the supply of intermediates, but this factory, which was commissioned in 2005 from a greenfield site, will now produce Hovione's two largest volume products.

"Hisyn represents an opportunity to both increase our manufacturing capacity and ensure a sustainable cost advantage. We find it important to provide our current customers with an assurance of competitive supply over the long run; and in addition we want to have a strong presence in new markets, such as Brazil, India and China, where price is decisive" said Miguel Calado, CFO.

The negotiation and the acquisition processes moved smoothly in part due to the experience Hovione has built in China over the last 3 decades. The Macau plant, with 5 previous FDA inspections and more than 10 years of contract manufacturing relationships in China, has enabled Hovione to effectively bridge cultures with China in every dimension: language, GMP, culture and business practices.

Luis Gomes, Vice President of Generics, and responsible for the investment and integration process added: "When we first came to the Canton fair in 1979 we were buying raw-materials that would be processed in Macau or in Portugal. For many years we felt we'd be better off being an important client of Chinese plants through contract manufacturing deals, because at that time there many JVs going very wrong. Now is the right time for Hovione to acquire infrastructure in China and tap into a growing market and leverage China's manufacturing abilities. We are planning to invest further monies in 2008 to effectively double Hisyn's manufacturing capacity".

Hovione is an international group specializing in the development and compliant production of active pharmaceutical ingredients, serving exclusively the pharmaceutical industry. In 2006 it had sales of US$94 million (Euro 70 million). With almost 50-year in process development, quality standards and advanced particle design technologies, Hovione offers APIs for all drug delivery systems, from oral to injectable and from inhalation to topical applications. With FDA inspected plants in Europe, the Far East and New Jersey, Hovione is committed to the highest levels of service and quality. Specializing in complex chemistry, Hovione offers services related to the development and manufacture of either a new chemical entity (NCE) for an exclusive contract manufacturing partner or an existing API for an off-patent product.

For further information about Hovione, please visit the Hovione site at http://www.hovione.com or contact Corporate Communications:

Isabel Pina,

+351-21-982-9362,

e-mail: hello@hovione.com.


'/>"/>
SOURCE Hovione
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
2. Middle East Pharma Manufacturing/Biotech is Ready to Boom
3. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
4. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
5. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
6. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
7. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
8. Genzyme Begins Major Expansion of Boston Manufacturing Facility
9. SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite
10. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
11. Thermo Fisher Scientific to Expand Manufacturing Operation for Single-Use Bioprocessing Containers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 ... ... opening applications to an early access program for SmartBiome -- a novel ... with the simultaneous specific enrichment and detection of hundreds of different genes. ...
(Date:12/6/2016)... ... December 06, 2016 , ... Almac ... pharmaceutical development and manufacturing organisation, today announced the formation of a ... leading CRO and the industry’s only Contract Commercial Organization (CCO). The partnership ...
(Date:12/6/2016)... ... December 06, 2016 , ... Symbios Technologies, ... that the company has engaged in a collaborative research partnership with Colorado State ... CSU Office of the Vice President for Research. This agreement is designed to ...
(Date:12/6/2016)... , Dec. 6, 2016 Zimmer Biomet Holdings, ... announced the pricing terms of its previously-announced cash ... aggregate purchase price (excluding accrued and unpaid interest ... and excluding fees and expenses related to the ... securities identified in the table below (collectively, the ...
Breaking Biology Technology:
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/29/2016)... , Nov. 29, 2016   Neurotechnology ... and object recognition technologies, today released FingerCell ... fingerprint recognition solutions that run on low-power, ... template using less than 128KB of memory, ... devices that have limited on-board resources, such ...
(Date:11/22/2016)... PUNE, India , November 22, 2016 According ... (Single-Factor: (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware ... to 2022", published by MarketsandMarkets, the market is expected to grow from ... at a CAGR of 16.79% between 2016 and 2022. ... ...
Breaking Biology News(10 mins):